Retatrutide is an investigational triple hormone receptor agonist, developer code LY3437943, that activates the GIP, GLP-1, and glucagon receptors at once. As of mid-2026 it carries no FDA or major-regulator approval and is available only inside clinical trials, so every condition tied to it is a research indication, not a labeled use. The published program clusters around obesity, type 2 diabetes, and fatty liver disease, with wider arms reaching into obesity-driven conditions such as knee osteoarthritis and cardiometabolic risk factors.
Retatrutide is investigational and unapproved as of mid-2026, with its largest research bodies in obesity, type 2 diabetes, and fatty liver disease, plus exploratory work in knee osteoarthritis and cardiometabolic risk.
Retatrutide holds investigational status, meaning a regulator has authorized supervised research use but has not concluded its benefits outweigh its risks for general medical use. It has no approved label, no approved dose, and no pharmacy availability. The published record is plain on the gray-market line: anything sold as retatrutide outside a registered trial sits outside that oversight and is documented as a safety hazard, not a legitimate treatment.
Retatrutide is an investigational compound with no approved label, dose, or pharmacy availability, and the only sanctioned route to receive it is enrollment in a registered clinical trial.
Obesity is the flagship indication, and the trials are built to test whether activating three metabolic receptors at once produces deeper, more durable weight reduction than current single- or dual-agonist drugs. A widely cited Phase 2 trial in adults with obesity reported mean reductions in the mid-twenty-percent range at the highest doses over roughly a year, figures that exceeded comparable GLP-1 therapies and helped justify a large Phase 3 program. The protocols use gradual dose escalation to limit gastrointestinal effects, and chronic weight management, not rapid loss, is the real endpoint.
In a widely cited Phase 2 obesity trial, retatrutide's highest doses produced mean weight reductions in the mid-twenty-percent range over roughly a year, exceeding comparable GLP-1 therapies and prompting a large Phase 3 program.
Type 2 diabetes is a core research indication because two of the three receptor targets, GIP and GLP-1, are established drivers of insulin secretion and blood-sugar control. The open mechanistic question is the glucagon receptor: glucagon ordinarily raises blood glucose, so a reasonable concern was whether adding glucagon activity would blunt glycemic control. The dedicated Phase 2 data answered that the combined GIP and GLP-1 effects dominated, and glucose control improved rather than worsened.
In a dedicated Phase 2 trial in adults with type 2 diabetes, retatrutide's higher doses lowered A1C by roughly two percentage points alongside meaningful weight loss, with glucose control improving rather than worsening despite the glucagon receptor component.
Fatty liver disease is a natural target because the condition is tightly bound to obesity and impaired metabolism, and because the molecule's glucagon receptor component acts directly on hepatic tissue. The spectrum runs from metabolic dysfunction-associated steatotic liver disease, formerly nonalcoholic fatty liver disease, to the more aggressive inflammatory and scarring form abbreviated MASH, where ongoing damage can progress to fibrosis and cirrhosis. The interest rests on a mechanism that drugs without a glucagon arm cannot reach.
An exploratory analysis from retatrutide's obesity program reported large reductions in liver fat with a high proportion of participants reaching normal liver-fat levels, which has driven interest in purpose-built MASH trials whose definitive results remain pending.
Retatrutide is tested across such a wide span of conditions because its mechanism works three complementary metabolic levers at once. Single agonists such as the early GLP-1 drugs work one lever and dual agonists work two, so the case for a triple agonist is that all three together can drive larger weight loss while improving glucose handling and reducing hepatic fat. That combination maps cleanly onto the indication set, while the glucagon arm remains the chief source of mechanistic uncertainty.
| Receptor | Primary action | Indication it explains |
|---|---|---|
| GLP-1 | Slows gastric emptying, curbs appetite, drives glucose-dependent insulin release | Obesity and diabetes |
| GIP | Reinforces insulin secretion, improves nutrient and fat handling | Diabetes |
| Glucagon | Raises energy expenditure, acts directly on the liver to mobilize and burn stored fat | Fatty liver disease |
Retatrutide's GLP-1 and GIP receptors drive the appetite and insulin effects behind its obesity and diabetes use while the distinguishing glucagon receptor raises energy expenditure and acts on the liver, explaining the fatty-liver interest and remaining the chief source of mechanistic uncertainty.
Educational use only. This article describes what the published scientific and clinical literature reports about Retatrutide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
